Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 5,400,601 | 2,795,407 | 1,439,329 | 12,800,790 | 4,665,770 |
| Depreciation Amortization | 2,477,389 | 2,477,074 | 2,404,302 | 2,492,270 | 3,339,050 |
| Accounts receivable | -572,629 | -369,886 | -254,796 | 149,842 | N/A |
| Accounts payable and accrued liabilities | 174,859 | 14,177 | 130,109 | 61,160 | N/A |
| Other Working Capital | 4,651,778 | 2,299,219 | 5,432,042 | 2,561,075 | 0 |
| Other Operating Activity | -891,648 | 1,699,927 | -345,601 | -14,137,136 | 525,740 |
| Operating Cash Flow | $11,240,350 | $8,915,918 | $8,805,384 | $3,928,001 | $8,530,560 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -210,898 | -15,466 | 795,561 | 417,417 | N/A |
| PPE Investments | -1,569,725 | -1,629,043 | -1,958,408 | -1,999,932 | -1,957,940 |
| Net Acquisitions | 38,709 | 596,714 | 105,713 | 11,089,840 | 337,860 |
| Purchase Of Investment | -13,348 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -261,621 | -784,879 | -712,888 | -435,765 | N/A |
| Other Investing Activity | -317,682 | -811,944 | -662,743 | -276,752 | -156,570 |
| Investing Cash Flow | $-2,072,944 | $-1,859,738 | $-1,719,876 | $9,230,573 | $-1,776,650 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 108,119 | N/A | 1,446,105 | N/A | N/A |
| Debt Issued | 13,532,200 | 2,877,890 | N/A | N/A | N/A |
| Common Stock Issued | 98,775 | 72,173 | 120,622 | 111,617 | N/A |
| Common Stock Repurchased | N/A | -83,772 | -100,292 | -151,371 | N/A |
| Dividend Paid | -5,241,760 | -5,034,053 | -6,573,205 | -5,923,346 | -6,333,640 |
| Other Financing Activity | -17,025,371 | -6,054,782 | -3,556,307 | -4,897,390 | -2,541,370 |
| Financing Cash Flow | $-8,528,037 | $-8,222,544 | $-8,663,077 | $-10,860,490 | $-8,875,010 |
| Exchange Rate Effect | 10,678 | -128,880 | 383,550 | -68,805 | 138,440 |
| Beginning Cash Position | 4,805,280 | 5,934,924 | 7,435,176 | 6,158,812 | 8,621,210 |
| End Cash Position | 5,455,328 | 4,639,680 | 6,241,157 | 8,388,094 | 6,638,540 |
| Net Cash Flow | $650,048 | $-1,295,244 | $-1,194,019 | $2,229,282 | $-1,982,660 |
| Free Cash Flow | |||||
| Operating Cash Flow | 11,240,350 | 8,915,918 | 8,805,384 | 3,928,001 | 8,530,560 |
| Capital Expenditure | -1,793,971 | -1,991,196 | -2,091,228 | -2,110,020 | N/A |
| Free Cash Flow | 9,446,379 | 6,924,722 | 6,714,156 | 1,817,981 | 8,530,560 |